RNA binding protein ZCCHC24 promotes tumorigenicity in triple-negative breast cancer

Triple-negative breast cancer (TNBC) lacks the expression of hormone and HER2 receptors and is highly malignant with no effective therapeutic targets. In TNBC, the cancer stem-like cell (CSC) population is considered to be the main cause of resistance to treatment. Thus, the therapeutic targeting of this population could substantially improve patient survival. Here, we identify the RNA-binding protein ZCCHC24 as enriched in the mesenchymal-like TNBC population. ZCCHC24 promotes the expression of a set of genes related to tumorigenicity and treatment resistance by directly binding to the cis-element "UGUWHWWA" in their mRNAs, thereby stabilizing them. One of the ZCCHC24 targets, ZEB1, is a transcription factor that promotes the expression of cancer stemness genes and reciprocally induces ZCCHC24 expression. ZCCHC24 knockdown by siRNAs shows a therapeutic effect and reduces the mesenchymal-like cell population in TNBC patient-derived xenografts. ZCCHC24 knockdown also has additive effects with the BET inhibitor JQ1 in suppressing tumor growth in TNBC patient-derived xenografts.

Authors

Institutions

Publication Details

Journal
EMBO Reports
Published
2024-10-17
DOI
https://doi.org/10.1038/s44319-024-00282-8
Citations
2
Primary Topic
RNA Research and Splicing
Type
article
Field-Weighted Citation Impact
0.47

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

RNA binding protein ZCCHC24 promotes tumorigenicity in triple-negative breast cancer

Yutaro Uchida, Yasuto Takeuchi, Ryota Kurimoto, Hiroshi Asahara et al.
2 citations
EMBO Reports
RNA Research and Splicing
0.47
article

RNA binding protein ZCCHC24 promotes tumorigenicity in triple-negative breast cancer

Yutaro Uchida, Yasuto Takeuchi, Ryota Kurimoto, Hiroshi Asahara, Tomoki Chiba, Takahide Matsushima, Iichiroh Onishi, Goshi Oda, Noriko Gotoh
article en
2 citations

Abstract

Triple-negative breast cancer (TNBC) lacks the expression of hormone and HER2 receptors and is highly malignant with no effective therapeutic targets. In TNBC, the cancer stem-like cell (CSC) population is considered to be the main cause of resistance to treatment. Thus, the therapeutic targeting of this population could substantially improve patient survival. Here, we identify the RNA-binding protein ZCCHC24 as enriched in the mesenchymal-like TNBC population. ZCCHC24 promotes the expression of a set of genes related to tumorigenicity and treatment resistance by directly binding to the cis-element "UGUWHWWA" in their mRNAs, thereby stabilizing them. One of the ZCCHC24 targets, ZEB1, is a transcription factor that promotes the expression of cancer stemness genes and reciprocally induces ZCCHC24 expression. ZCCHC24 knockdown by siRNAs shows a therapeutic effect and reduces the mesenchymal-like cell population in TNBC patient-derived xenografts. ZCCHC24 knockdown also has additive effects with the BET inhibitor JQ1 in suppressing tumor growth in TNBC patient-derived xenografts.

EMBO ReportsVol. 25(12)
Kanazawa University (JP), Tokyo Institute of Technology (JP), Scripps Research Institute (US), Systems Biology Institute (JP), The University of Tokyo (JP)
Cancer Research Institute, Japan Agency for Medical Research and Development, Cancer Research Institute, Kanazawa University, Kanazawa University, Tokyo Medical and Dental University, National Institutes of Health, Japan Society for the Promotion of Science
Good health and well-being
Openalex Percentile: Top 35%
RNA Research and Splicing
0.47
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.